-
公开(公告)号：US20210299224A1
公开(公告)日：2021-09-30
申请号：US17301123
申请日：2021-03-25
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： SangKon OH , Sandra ZURAWSKI , Hyemee JOO , Gerard ZURAWSKI
Abstract: Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.
-
公开(公告)号：US20170095573A1
公开(公告)日：2017-04-06
申请号：US15316040
申请日：2015-06-02
Applicant: Baylor Research Institute
Inventor： SangKon OH , Bob Kane , Gerard Zurawski
CPC classification number: A61K47/543 , A61K47/6803 , A61K47/6849 , A61K2039/505 , A61K2039/577 , C07K16/2851 , C07K2317/24 , C07K2317/33 , C07K2317/75 , C07K2317/76
Abstract: Described herein are therapeutic approaches with immune modifiers of the Th2 pathway for the treatment of allergic and inflammatory diseases. Aspects of the disclosure relate to methods for decreasing Th2-type cell responses in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an anti-Dectin-1 antibody or antigen binding fragment thereof operatively linked to a TLR agonist.
-
公开(公告)号：US20160331825A1
公开(公告)日：2016-11-17
申请号：US15111357
申请日：2015-01-13
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： SangKon OH , Sandra ZURAWSKI , Gerard ZURAWSKI
IPC: A61K39/12 , A61K39/395 , C12N7/00 , C07K16/28 , C07K14/005
CPC classification number: A61K39/12 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K2039/505 , A61K2039/53 , A61K2039/55511 , A61K2039/585 , A61K2039/6056 , A61K2039/70 , C07K14/005 , C07K16/2878 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2319/74 , C07K2319/91 , C12N7/00 , C12N2710/20034
Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV 16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
Abstract translation: 实施例涉及针对人乳头状瘤病毒（HPV）和HPV相关疾病（包括多种类型的癌症）的新型疫苗。 HPV疫苗由抗人树突状细胞（DC）表面受体抗体，包括HPV16和18的CD40和E6 / 7蛋白组成。所述技术不限于制备针对HPV16和HPV18相关疾病的疫苗， 可用于从任何类型的HPV中制备携带E6 / 7的疫苗。 描述的HPV疫苗可以靶向DCs，主要和专业抗原呈递细胞（APC），并且可以诱导和激活有效的HPV E6 / 7特异性和强的CD4 +和CD8 + T细胞应答。 HPV疫苗可用于预防HPV感染和HPV相关疾病以及用于治疗HPV相关疾病，包括癌症。
-
公开(公告)号：US20250018025A1
公开(公告)日：2025-01-16
申请号：US18670211
申请日：2024-05-21
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： SangKon OH , Dapeng LI , Jacques Banchereau , Gerard Zurawski , Sandra Zurawski
IPC: A61K39/145 , A61K39/00 , A61K47/68 , A61K51/10 , C07K14/005 , C07K14/195 , C07K14/37 , C07K14/405 , C07K14/435 , C07K16/28 , C12N5/0784 , C12N7/00
Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.
-
公开(公告)号：US20190314481A1
公开(公告)日：2019-10-17
申请号：US16397214
申请日：2019-04-29
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： SangKon OH , Sandra ZURAWSKI , Gerard ZURAWSKI
IPC: A61K39/12 , C07K14/005 , A61K39/395 , C07K16/28 , C12N7/00
Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
-
Patent Agency Ranking
公开(公告)号：US20170349661A1
公开(公告)日：2017-12-07
申请号：US15501526
申请日：2015-08-03
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： Yong-Jun LIU , Sandra ZURAWSKI , SangKon OH , Shino HANABUCHI , Haruyuki FUJITA , Hideki UENO , Patrick BLANCO , Hyemee JOO
CPC classification number: C07K16/2875 , A61K2039/505 , A61K2039/545 , C07K2317/24 , C07K2317/565 , C07K2317/76
Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-α and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell- (Tfh) responses that may contribute to the pathogenicity of autoimmune disease.
-
公开(公告)号：US20250121048A1
公开(公告)日：2025-04-17
申请号：US18990184
申请日：2024-12-20
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： SangKon OH , Sandra ZURAWSKI , Gerard ZURAWSKI
IPC: A61K39/12 , A61K39/00 , A61K39/395 , C07K14/005 , C07K16/28 , C12N7/00
Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
-
公开(公告)号：US20210308242A1
公开(公告)日：2021-10-07
申请号：US17301704
申请日：2021-04-12
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： Gerard ZURAWSKI , Jacques F. Banchereau , Anne-Laure FLAMAR , Peter KLUCAR , Keiko AKAGAWA , Sandra ZURAWSKI , SangKon OH
IPC: A61K39/00 , C07K16/28 , C07K14/435
Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
-
公开(公告)号：US20210268097A1
公开(公告)日：2021-09-02
申请号：US17194779
申请日：2021-03-08
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： SangKon OH , Sandra ZURAWSKI , Gerard ZURAWSKI
IPC: A61K39/12 , A61K39/395 , C07K16/28 , C07K14/005 , C12N7/00
Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
-
公开(公告)号：US20250144191A1
公开(公告)日：2025-05-08
申请号：US19010936
申请日：2025-01-06
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： SangKon OH , Gerard ZURAWSKI
Abstract: Methods and compositions for treating multiple sclerosis using dendritic cell anti-ASGPR antibodies fused to myelin basic protein or myelin oligodendrocyte glycoprotein are provided.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.018 seconds)
